ITGA4 and B-cell chronic lymphocytic leukemia: Nevertheless, when comparing the extent of nodal response in CD49d− and CD49d+ CLL, a trend of lower response was already observable after 2 mo of ibrutinib treatment in CD49d+ CLL, a difference that became significant after 6 and 12 mo.